Submitted by Anonymous (not verified) on 27 October 2023 - 11:06
Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 16, Status: Authorised
Source: